Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 8 of 8 entries
View as:

Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03353831 Org: User:
Start: 09/11/18 End: 03/11/25 Due: 03/11/26

Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi

Phase: N/A Priority: Normal
NCT ID: NCT05126342 Org: User:
Start: 11/01/23 End: 11/01/26 Due: 11/01/27

Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04274426 Org: User:
Start: 10/13/21 End: 12/31/26 Due: 12/31/27

Prevalence of BRCA in Patients With Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02222883 Org: User:
Start: 03/31/15 End: 04/01/21 Due: 04/01/22

Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01837251 Org: User:
Start: 05/31/13 End: 01/31/21 Due: 01/31/22

Pembrolizumab in Combination With Lenvatinib in Pts With Recurrent, Persistent, Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy

Phase: N/A Priority: Normal
NCT ID: NCT05903833 Org: User:
Start: 04/01/25 End: 10/30/29 Due: 10/30/30

WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC

Phase: N/A Priority: Normal
NCT ID: NCT04644289 Org: User:
Start: 05/05/22 End: 06/30/28 Due: 06/30/29

Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03690739 Org: User:
Start: 08/09/19 End: 03/03/21 Due: 03/03/22